A Multicenter Open-label Clinical Study on the Prevention of Premature Ovarian Failure After HSCT

Launched by FIRST AFFILIATED HOSPITAL XI'AN JIAOTONG UNIVERSITY · Dec 26, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a potential way to protect women's fertility after they undergo a treatment called Hematopoietic Stem Cell Transplantation (HSCT), which is often used to treat blood cancers. Sometimes, the chemotherapy and radiation needed before the transplant can harm the ovaries, leading to a condition called premature ovarian failure (POF) that can cause infertility and affect quality of life. The researchers want to see if a medication called Gonadotropin-releasing hormone analogues (GnRHa) can help maintain ovarian function in women aged 18 to 45 who are about to receive HSCT.

To be eligible for the trial, participants must be women who have been diagnosed with certain blood disorders and have normal ovarian function before starting treatment. They also need to be willing to participate in the study and sign a consent form. Unfortunately, women who have already experienced menopause, had surgeries affecting their reproductive organs, or have certain medical conditions may not qualify. This trial is still in the planning stages and has not yet started recruiting participants, but it aims to gather important information that could help protect women's fertility during cancer treatment.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed with acute leukemia, MDS, lymphoma, multiple myeloma, SAA and other hematological diseases, with the indications for autologous or allogeneic hematopoietic stem cell transplantation.
• • Female, aged 18-45 years.
• • Ovarian function was normal before treatment.
• • Volunteer to participate in clinical research and sign the informed consent form.
• Exclusion Criteria:
• • No menstruation before treatment, undergone hysterectomy or ovarian surgery.
• • Abnormal sexual development.
• • Received radiotherapy.
• • Combined with tumors affecting gonadal function.
• • Deep vein thrombosis.
• • Hypertension, liver and/or kidney dysfunction cannot tolerate hematopoietic stem cell transplantation.